FibroBiologics (FBLG) Operating Expenses (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Operating Expenses of $4.0 million for Q2 2026, down 10.18% year-over-year from $4.5 million in Q2 2025, and down 20.42% on a QoQ basis from $5.1 million in Q1 2026.
FibroBiologics (FBLG) Operating Expenses (2023 - 2026) Analysis & Trends
FibroBiologics has reported Operating Expenses for 4 years, with the latest figure at $4.0 million in Q2 2026.
- Operating Expenses for Q2 2026 came in at $4.0 million, down 10.18% year-over-year; the trailing twelve-month figure through Jun 2026 was $16.7 million (up 4.0% YoY), and the FY2025 annual result was $16.6 million, up 21.2% from the prior year.
- Operating Expenses fell to $4.0 million in Q2 2026, from $5.1 million in the prior quarter.
- Over five years, Operating Expenses peaked at $5.1 million in Q1 2026 and troughed at $2.1 million in Q3 2023.
- A 4-year average of $3.5 million and a median of $3.4 million in 2024 frame the typical range for Operating Expenses.
- The widest annual swing landed in 2024, when Operating Expenses jumped 63.35%; it then sank 30.23% in 2025.
- A 4-year view of Operating Expenses shows it stood at $2.5 million in 2023, then jumped by 49.68% to $3.7 million in 2024, then sank by 30.23% to $2.6 million in 2025, then surged by 55.71% to $4.0 million in 2026.
- Per Business Quant data, the three most recent Operating Expenses figures were $4.0 million in Q2 2026, $5.1 million in Q1 2026, and $2.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | FibroBiologics | 8.15 Mn | 8.15 Mn | - | 4.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.03 Mn |
| Mar 31, 2026 | 5.07 Mn |
| Dec 31, 2025 | 2.59 Mn |
| Sep 30, 2025 | 5.04 Mn |
| Jun 30, 2025 | 4.49 Mn |
| Mar 31, 2025 | 4.53 Mn |
| Dec 31, 2024 | 3.71 Mn |
| Sep 30, 2024 | 3.35 Mn |
| Jun 30, 2024 | 3.22 Mn |
| Mar 31, 2024 | 3.45 Mn |
| Dec 31, 2023 | 2.48 Mn |
| Sep 30, 2023 | 2.05 Mn |
| Jun 30, 2023 | 2.09 Mn |
| Mar 31, 2023 | 2.27 Mn |